鶹ý

Ozempic for Alzheimer's? What Drives Brain Age; Primary Care Alzheimer's Guideline

— News and commentary from the world of neurology and neuroscience

MedpageToday
Neuro Break over a computer rendering of neurons.

Two clinical trials (Ozempic, Wegovy) as an early Alzheimer's treatment are expected to wrap up in 2025. (New Scientist)

Researchers say for Parkinson's disease or epilepsy may enter the clinic soon. (Nature)

Vascular-related lifestyles and health were , with healthier profiles tied to younger-looking brains at age 70. (Alzheimer's & Dementia)

In phase III studies of , oral atogepant (Qulipta) showed efficacy and improved functional measures within the first 4 weeks of treatment. (Neurology)

Topline results were positive in the phase II study of investigational CT1812 in people with , Cognition Therapeutics said.

The FDA cleared Onward Medical's ARC-EX to treat chronic spinal cord injury.

The Alzheimer's Association issued a on evaluating, testing, and counseling about Alzheimer's disease and dementia in primary care. (Alzheimer's & Dementia)

A close look at the effects of mutations in C21ORF2, a gene linked with amyotrophic lateral sclerosis (ALS), showed that were dysfunctional. (Brain)

Compared with children who played individual sports, those involved in team sports or both types of sports showed at ages 10 and 11. (JAMA Network Open)

The New York Times looked at MSW (1932-2023), who developed validation therapy to connect with people who had severe dementia.

  • Judy George covers neurology and neuroscience news for 鶹ý, writing about brain aging, Alzheimer’s, dementia, MS, rare diseases, epilepsy, autism, headache, stroke, Parkinson’s, ALS, concussion, CTE, sleep, pain, and more.